Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione won the 2023 CDMO Leadership Award across all six categories across all three groups of respondents
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
Silicon Republic, October 2, 2020
Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Hovione offers simple, patented and globally competitive dry powder inhalers – Disposable, Capsule, Blister and Large Dose DPIs – which are available for fully integrated turn-key development with formulation and for licensing.
Google Chrome
Safari
Firefox
Edge